Satoshi Hashigaki

537 total citations
19 papers, 406 citations indexed

About

Satoshi Hashigaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Satoshi Hashigaki has authored 19 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in Satoshi Hashigaki's work include Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Satoshi Hashigaki is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Satoshi Hashigaki collaborates with scholars based in Japan, United States and Italy. Satoshi Hashigaki's co-authors include Yoshiko Umeyama, Shinji Ohno, Norikazu Masuda, Hiroji Iwata, Yuko Mori, Hirofumi Mukai, Kenichi Inoue, Emiko Ohki, Yoshiaki Rai and Masato Takahashi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Satoshi Hashigaki

19 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Hashigaki Japan 11 306 279 111 56 51 19 406
A. García Spain 10 183 0.6× 180 0.6× 76 0.7× 84 1.5× 30 0.6× 22 339
Xiangying Meng China 11 222 0.7× 166 0.6× 58 0.5× 34 0.6× 27 0.5× 32 356
Manuel Magerle Austria 8 244 0.8× 275 1.0× 136 1.2× 147 2.6× 28 0.5× 9 438
Junichi Tomomatsu Japan 13 232 0.8× 158 0.6× 37 0.3× 106 1.9× 33 0.6× 49 431
Karen Giselle Chee United States 7 182 0.6× 163 0.6× 40 0.4× 102 1.8× 18 0.4× 9 380
Sabine Turri France 8 157 0.5× 115 0.4× 60 0.5× 152 2.7× 41 0.8× 12 333
Maria Bassanelli Italy 10 419 1.4× 326 1.2× 26 0.2× 99 1.8× 33 0.6× 23 547
Ichiro Nakachi Japan 13 263 0.9× 374 1.3× 56 0.5× 269 4.8× 20 0.4× 34 629
Joaquín Mosquera Spain 12 305 1.0× 226 0.8× 21 0.2× 53 0.9× 24 0.5× 39 457
Friedrich Graf Finckenstein United States 10 332 1.1× 175 0.6× 24 0.2× 139 2.5× 16 0.3× 17 481

Countries citing papers authored by Satoshi Hashigaki

Since Specialization
Citations

This map shows the geographic impact of Satoshi Hashigaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Hashigaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Hashigaki more than expected).

Fields of papers citing papers by Satoshi Hashigaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Hashigaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Hashigaki. The network helps show where Satoshi Hashigaki may publish in the future.

Co-authorship network of co-authors of Satoshi Hashigaki

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Hashigaki. A scholar is included among the top collaborators of Satoshi Hashigaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Hashigaki. Satoshi Hashigaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Takahashi, Masato, Norikazu Masuda, Reiki Nishimura, et al.. (2020). Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. Cancer Medicine. 9(14). 4929–4940. 15 indexed citations
3.
Masuda, Norikazu, Hirofumi Mukai, Kenichi Inoue, et al.. (2019). Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer. 26(5). 637–650. 10 indexed citations
4.
Endo, Yutaka, et al.. (2019). Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. Japanese Journal of Clinical Oncology. 49(7). 676–686. 9 indexed citations
5.
Ito, Tetsuhide, Masayuki Tori, Satoshi Hashigaki, et al.. (2019). Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. Japanese Journal of Clinical Oncology. 49(4). 354–360. 11 indexed citations
6.
Masuda, Norikazu, Kenichi Inoue, Rikiya Nakamura, et al.. (2018). Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. International Journal of Clinical Oncology. 24(3). 262–273. 41 indexed citations
7.
Mukai, Hirofumi, Chikako Shimizu, Norikazu Masuda, et al.. (2018). Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. International Journal of Clinical Oncology. 24(3). 274–287. 56 indexed citations
8.
Masuda, Norikazu, Reiki Nishimura, Masato Takahashi, et al.. (2018). Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study. Cancer Science. 109(3). 803–813. 28 indexed citations
9.
Nishio, Makoto, Dong‐Wan Kim, Yi‐Long Wu, et al.. (2017). Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment. 50(3). 691–700. 45 indexed citations
10.
Shimatsu, Akira, et al.. (2016). Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. Endocrine Journal. 63(4). 337–347. 10 indexed citations
11.
Tamura, Kenji, Hirofumi Mukai, Yoichi Naito, et al.. (2016). Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Science. 107(6). 755–763. 63 indexed citations
12.
Igarashi, H, Takuji Okusaka, Tetsuhide Ito, et al.. (2013). Phase II Study of Sunitinib (SU) in Japanese Patients with Well-Differentiated Pancreatic Neuroendocrine Tumor (NET). Annals of Oncology. 24. ix82–ix82. 2 indexed citations
13.
Iwata, Hiroji, Norikazu Masuda, Shinji Ohno, et al.. (2013). A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Research and Treatment. 139(2). 441–451. 40 indexed citations
14.
Boku, Narikazu, Kei Muro, Nozomu Machida, et al.. (2013). Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Investigational New Drugs. 32(2). 261–270. 12 indexed citations
15.
Yoshino, Takayuki, Kentaro Yamazaki, Tetsuya Hamaguchi, et al.. (2012). Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.. PubMed. 32(3). 973–9. 6 indexed citations
16.
Ito, Tetsuhide, Takuji Okusaka, Toshirou Nishida, et al.. (2012). Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investigational New Drugs. 31(5). 1265–1274. 34 indexed citations
17.
Okusaka, Takuji, Tetsuhide Ito, Toshirou Nishida, et al.. (2012). Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET).. Journal of Clinical Oncology. 30(4_suppl). 381–381. 4 indexed citations
18.
Tsuji, Yasushi, Taroh Satoh, Akihito Tsuji, et al.. (2012). First‐line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study. Cancer Science. 103(8). 1502–1507. 13 indexed citations
19.
Togo, Kanae, et al.. (2011). Clinically Important Effects in New Drug Development. Drug Information Journal. 45(6). 805–810. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. García Breakdown of academic impact, for papers by Xiangying Meng Breakdown of academic impact, for papers by Manuel Magerle Breakdown of academic impact, for papers by Junichi Tomomatsu Breakdown of academic impact, for papers by Karen Giselle Chee Breakdown of academic impact, for papers by Sabine Turri Breakdown of academic impact, for papers by Maria Bassanelli Breakdown of academic impact, for papers by Ichiro Nakachi Breakdown of academic impact, for papers by Joaquín Mosquera Breakdown of academic impact, for papers by Friedrich Graf Finckenstein
Rankless by CCL
2026